Novartis tomorrow bout time, page-57

To add to that -

Patients that are eligible for the Molecular “EMPATHY” trial must be experiencing a minimum of two predetermined mild or moderate symptoms within a week prior to diagnosis. – these symptoms may be respiratory related but respiratory is not singled out and could be plethora of others.

The trial is aiming to prevent worsening symptoms and hospitalization for patients in the early stages of the of infection.

Below is the link to the announcement on the Novartis website. Respiratory was not once mentioned throughout the text.

https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19